Market Overview

Credit Suisse Starts Patheon At Neutral Following Nearly 30% Rally

Share:
Credit Suisse Starts Patheon At Neutral Following Nearly 30% Rally

Patheon NV (NYSE: PTHN) shares have appreciated 29 percent since the IPO on July 21, and the stock is currently trading at a 10 percent premium to the relevant pharmaceutical outsourcing companies.

Credit Suisse’s Erin Wilson initiated coverage of the company with a Neutral rating and price target of $30.

Competitive Advantages

Wilson believes the clear competitive advantages in the company’s “comprehensive end-to-end services should drive revenue growth ahead of the industry, with meaningful operating margin leverage and capital deployment opportunities to support double-digit EPS growth LT.”

The analyst also stated that the increasing health care utilization and innovation in a difficult regulatory and reimbursement environment was likely to drive higher outsourcing of pharmaceutical development and manufacturing processes, especially with therapeutics becoming increasingly complex.

Related Link: Morgan Stanley Expects "Above-Market Organic Growth" For Patheon, Initiates At Overweight

Differentiated Scope

According to the Credit Suisse report, “PTHN focuses on the $40+ billion CDMO market, growing 5–7 percent annually, where we estimate outsourcing to rise to 35+ percent over the next five years.”

Patheon has manufactured 21 percent of outsourced FDA approved drugs over the last decade, and Wilson expects incremental market share gains to be driven by the company leveraging its differentiated scope that extends from drug development to the commercialization lifecycle.

“Greater cross-selling should foster longer term customer relationships and more predictable, recurring revenue streams. Disciplined cost structure initiatives should drive material operating margin expansion in the coming years,” the analyst added.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for PTHN

DateFirmActionFromTo
Jun 2017Leerink SwannDowngradesOutperformMarket Perform
Jun 2017Raymond JamesDowngradesOutperformMarket Perform
Jun 2017JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for PTHN
View the Latest Analyst Ratings

 

Related Articles (PTHN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Initiation Analyst Ratings Movers General Best of Benzinga

Latest Ratings

StockFirmActionPT
WLKCFRADowngrades37.0
KMXCFRAMaintains75.0
KIDSNeedhamMaintains46.0
LKNeedhamSuspends40.0
BSXNeedhamMaintains43.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com